We investigated the long-term efficacy and tolerability of add-on Topiramate, used under placebo- controlled conditions, in 13 adult refractory epileptic patients, mostly with complex partial seizures. Overall, 4 patients (33%) were still on Topiramate (400 to 1000 mg/daily) after a mean period of 30 months. CNS-related side effects occurred in 10 patients and were usually transitory and mild. We conclude that Topiramate maintains its benefit on long-term follow-up in one third of the patients initially exposed to the study drug.
|Translated title of the contribution||Topiramate in the treatment of drug-resistant epilepsy: A long-term follow-up study|
|Number of pages||2|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - 1996|
ASJC Scopus subject areas
- Clinical Neurology